10 programs selected to help support healthcare
capacity building in resource-constrained countries
More than $1 million in total provided to
expand essential cancer care services
Celgene Corporation (NASDAQ:CELG) today announced ten programs
selected for funding under its Celgene Cancer Care Links™ program,
an initiative designed to support cancer healthcare capacity
building in resource-constrained countries around the world.
The programs selected are expected to support established
institutions partnering with in-country medical centers that
provide essential cancer care services including awareness and
education, prevention, diagnosis and care. The Celgene Cancer Care
Links program is an initiative of Celgene Global Health, which
focuses on healthcare challenges facing patients in developing
parts of the world.
“Celgene Cancer Care Links is another program we have created to
make a meaningful impact for patients and healthcare systems around
the world,” said Mark J. Alles, Chairman and Chief Executive
Officer of Celgene. “We are excited to announce the first round of
grants through this initiative and wish these world-renowned
organizations and institutions great success.”
Recipients of Celgene Cancer Care Links grants include:
Program Title Organization
Partner Institution Standard of care
for pediatric Kaposi Sarcoma in Lilongwe, Malawi
Baylor College of Medicine, Texas Children’s Hospital,
Houston, TX Baylor College of Medicine
Children’s Foundation – Malawi National cervical cancer prevention
program in Haiti: scaling up a pilot project
Basic Health International, New York, NY St.
Luke’s Foundation/Carmelle Voltaire Women’s Center - Haiti
Risk-adapted treatment of pediatric Burkitt Lymphoma in sub-Saharan
Africa Baylor College of Medicine, Texas
Children’s Hospital, Houston, TX Baylor
College of Medicine Children’s Foundation – Uganda Point-of-care
diagnostics for lymphoma Dana-Farber Cancer
Institute, Brookline, MA La Nacional Contra el
Cancer (INCAN) – Guatemala Implementation of Tanzania’s National
Cancer Treatment Guidelines at Ocean Road Cancer Institute
University of San Francisco (UCSF) Foundation, San
Francisco, CA Ocean Road Cancer Institute –
Tanzania Advancing pharmacy care for cancer patients in South Asia
Vennue Foundation, Stamford, CT
Healthcare centers providing cancer care in Bangladesh and
Nepal Implementing multidisciplinary cervical cancer care in Nepal
American Society of Clinical Oncology (ASCO),
Alexandria, VA Bhaktapur Cancer Hospital –
Nepal Improve diagnosis and treatment of cancer in children,
adolescents and young adults in Ghana World
Child Cancer, London, UK Korle Bu Teaching
Hospital – Ghana Optimizing adherence to standard therapy delivery
in non-metastatic breast cancer patients in Botswana
University of Pennsylvania, Philadelphia, PA
Princess Marina Hospital – Botswana Long-distance learning
platform (ONCOENSINO) Brazilian Lymphoma and
Leukemia Society (ABRALE), Sao Paulo, Brazil
“The programs we are supporting through Celgene Cancer Care
Links address many important areas of cancer diagnosis and care,”
said Joe Camardo, M.D., Senior Vice President, Global Health and
Corporate Affairs Medical Strategy at Celgene. “For patients in
resource-constrained nations like these, programs addressing this
area fill a vital need in healthcare capacity.”
About Celgene Cancer Care Links™
Celgene Cancer Care Links is a grant program to support health
care capacity initiatives that enhance patient cancer care in
resource-constrained countries. Celgene Cancer Care Links is a
demonstration of Celgene's commitment to improving the lives of
patients worldwide.
The Celgene Cancer Care Links program is also featured in Access
Accelerated, a group of over 20 biopharmaceutical companies
developing innovative and sustainable solutions to improve access
to non-communicable disease treatment and care in low and
middle-income countries. In addition to each company committing to
do more with their individual programs, Access Accelerated also
includes partnerships with the World Bank and the Union of
International Cancer Control. Access Accelerated is part of the
private sector’s commitment to achieving the United Nations
Sustainable Development Goal target to reduce premature deaths from
NCDs by 2030.
For more information on these programs, as well as Celgene’s
Corporate Responsibility and Global Health efforts, please visit
the following links:
http://www.celgene.com/responsibility/global-health/celgene-cancer-care-links/
http://www.AccessAccelerated.org
https://www.celgene.com/responsibility/global-health/
https://www.celgene.com/responsibility/
To read our latest Corporate Responsibility report, please visit
https://media.celgene.com/content/uploads/Celgene-2018-CR-Report.pdf
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social Media: @Celgene, Pinterest,
LinkedIn, Facebook and YouTube.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Celgene undertakes no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors, many of which are discussed in more detail in
Celgene's Annual Report on Form 10-K and other reports filed with
the Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181217005342/en/
Celgene
CorporationInvestors:+1-908-673-9628ir@celgene.comorMedia:+1-908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024